Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Ibio Inc IBIO

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu... see more

NYSEAM:IBIO - Post Discussion

Ibio Inc > $iBio - What goes up behind the scenes ... ???
View:
Post by FelixFun on Aug 09, 2020 5:47am

$iBio - What goes up behind the scenes ... ???

$IBIO Trying to get to the bottom of this 25% discussion people have been talking about, we dug into the SEC Filings and tried to create a timeline. Nagging question: Why did Dart's lawyer (Sullivan) and iBio's lawyer (Abramowitz) both use the June's date float of 119 million given that there was 23 million shares issued since then? What we came up with is that Dart had an opportunity turn a profit, dilute himself through conversion, and gain shares/voting power while buying millions of shares cheaply and staying under the radar of the SEC and/or helping iBio get BARDA funding (which would be very beneficial to him). Or forget the 25% issue all together and keep it simple. He had a chance to recoup his investment costs/turn a profit, and gain voting power, and buy more shares. Keep in mind: He couldn't buy until the end of June (standstill). Some Things to Research in regards to the 25% Threshold. § 120.37 . §120.1(c)(1)

Source: https://stocktwits.com/iBio_Cultist

Float, Dart, Shares
BARDA V entures

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities